BPC-157 Guide: Reconstitution, Reported Dosage & Stacks

BPC-157 at a glance

What it is

BPC-157 ("Body Protection Compound-157") — a synthetic 15-amino-acid peptide based on a sequence found in human gastric juice.

Researched for

Gastrointestinal and soft-tissue/tendon repair contexts (preclinical/animal models).

Commonly reported range

~250–500 mcg per day (community-reported; some report split AM/PM dosing).

Route reported

Subcutaneous injection most common; oral and localized use also discussed.

Reported frequency

Once or twice daily (short plasma half-life).

Reported cycle

~4–8 weeks, often with a break; examples like 4 weeks on / 2 off.

Plasma half-life

Reported under 30 minutes.

Regulatory status

Not FDA-approved for these uses; WADA-prohibited; research/educational use only.

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

BPC-157 is a stable synthetic pentadecapeptide derived from a partial sequence of body-protection compound found in human gastric juice. In preclinical research it is studied for its reported effects on tissue repair — including tendon, ligament, muscle, and gut-lining models. The mechanisms most cited in the literature are promotion of angiogenesis (new blood-vessel formation, linked to VEGFR2 signaling), modulation of growth-factor and nitric-oxide pathways, and interaction with the gut-brain axis. Most published evidence is from animal and in-vitro studies; robust human clinical trial data is limited.

Researched effects

Reported and researched (primarily preclinical) contexts include: accelerated healing of tendon-to-bone and muscle injuries in animal models; protective effects on the gastrointestinal tract (studied in models of ulcers and inflammatory injury); and cytoprotective/angiogenic effects. Community reports frequently describe use around soft-tissue recovery. These are research findings and anecdotal reports, not guaranteed outcomes; BPC-157 is not proven or approved to treat any condition in humans.

Dosage — reported ranges (overview)

Community-reported ranges commonly cluster around 250–500 mcg per day, sometimes split into two doses given the short half-life. Some protocols describe localized subcutaneous injection near the area of interest; others describe systemic dosing. Reported cycle lengths are typically 4–8 weeks. These are examples of what is reported, not a recommendation; there is no FDA-approved human dose.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

BPC-157 ships lyophilized (freeze-dried) and is reconstituted with bacteriostatic water. Concentration (mcg per unit) = total mcg in vial ÷ (mL of bac water × 100) — using a U-100 insulin syringe (100 units = 1 mL). Worked example for a 5 mg vial:

This is concentration math, not a dose recommendation.

Injection / administration basics

Reported administration is typically subcutaneous using a U-100 insulin syringe; some sources describe localized subcutaneous injection near the area of interest. General handling concepts — sterile technique, site rotation, timing — are covered here as general information; the detailed workflow and site-rotation guidance come with All-Access Lifetime, which includes the printable protocol sheet and injection log for every compound. This is general educational information, not a personal administration protocol; a qualified professional should guide any actual use.

Half-life & frequency rationale

BPC-157's plasma half-life is reported at under 30 minutes, which is why community protocols often describe once- or twice-daily dosing rather than less frequent administration. Localized effects are sometimes discussed as outlasting plasma presence, but this is not well-established in humans.

Stacking — overview

BPC-157 is most often discussed alongside TB-500, GHK-Cu, and KPV. Each combination is covered in depth — the mechanism-level rationale, what is reported in practice, and combination-specific cautions — in the paid BPC-157 Stacking Module included with this guide.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Lyophilized (unmixed): store cold; long-term typically −20°C / freezer; stable refrigerated short-term.
• Reconstituted: refrigerate (~2–8°C); commonly reported usable window ~2–4 weeks; keep away from light; do not freeze once mixed.

Evidence File

The BPC-157 Evidence File: Three Registry Records, Five Human Studies, and the Route Nobody Has Studied

Most public accounts of what is known about BPC-157 in humans are written from secondary sources, and the secondary sources disagree with the primary ones. This module rebuilds the record from documents fetched directly: every ClinicalTrials.gov entry returned across sixteen named synonym and development-code searches, the complete field set of each record including the submission-tracking and annotation blocks most readers never open, and the FDA briefing document prepared for the July 2026 Pharmacy Compounding Advisory Committee, whose Appendix 1 is the fullest public inventory of human BPC-157 exposure located for this file. Every search is named, every route and amount is attributed to the document that states it, and registry facts are kept separate from what review articles say about them.

• 3 registered trials, from a sweep of 16 synonym and code terms
• Results released to the registry in 2016, then un-released
• 1 randomised human trial; between-group CI runs -4.84 to 1.62
• 0 published human studies used the subcutaneous route

Sourcing File

The BPC-157 Sourcing File: Two Substances Under One Name, and the Arithmetic Between the Label and the Molecule

BPC-157 is sold under a common name that maps to two different active ingredients with different registry identifiers, different CAS numbers and different molecular weights, and the certificates circulating in the market routinely mix the two. This module works from the identifier records themselves, re-fetched for this file, and from the two certificates of analysis a federal reviewer read line by line and tabulated: which numbers a document should carry, which mass a spectrometry line should print, how counter-ion and water content move the amount of peptide actually in a vial, and which tests the market's documents leave out. Every computation is shown rather than asserted, so each one can be checked.

• Two UNIIs, two CAS numbers, one common name shared between them
• 1418.70416 Da neutral monoisotopic; 1419.5 is the average mass
• A 5 mg acetate vial can work out to about 4.2 mg of free base
• FDA: no endotoxin, aggregate or bioburden result on either nominator CoA

Benefit & Outcome Review

The BPC-157 Benefit and Outcome Review: Every Marketed Claim Graded Against What Was Actually Measured

BPC-157 is marketed on a set of claims that are usually stated without saying what kind of subject produced them. This module separates the tiers and keeps them separate in every sentence: a person given the compound and measured, a live animal, or cells and excised tissue in a bath. Each marketed claim is taken in turn with the named studies behind it, their species, routes, amounts, comparators, time courses, effect sizes where the authors published numbers, non-responder counts where they were reported, and the limitations the authors themselves wrote down. It also names the statements that the underlying papers do not support, including one where a paper's own title and its own abstract disagree.

• 36 studies in one systematic review: 35 preclinical, 1 clinical
• No dose-response: 10 ng/kg and 10 mcg/kg gave the same effect size
• 3 FAERS reports, all injectable, one positive on rechallenge
• 0 human trials comparing it against an approved therapy

Guide FAQ

Quick answers about guide scope, access, and educational use context.